Bogle Ohara News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Canntab Granted 2nd Patent For Immediate Release Cannabidiol Formulation Tablets News provided by Share this article Company or Canntab ), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is thrilled to announce the Canadian Intellectual Property Office ( CIPO ) has allowed Canadian Patent No. CA 3050150 to Canntab, related to its proprietary cannabidiol formulations with a priority date of January 23, 2017. The term of the patent expires on January 22, 2038.  Canntab s Legal Counsel on intellectual property, Gavin Bogle of Magyar, Bogle & O Hara LLP said, The allowance of Canntab s patent by the Canadian Intellectual Property Office provides fundamental intellectual protection for Canntab s innovative tableting technology and validates the years of research and development the company has conducted. The Company now has patent protection in Canada and the USA providing an international scope to the Company s expanding

United statesGavin bogleLarry latowskyBogle oharaCompany or canntabCanntab therapeutics limitedCannabis researchBiden administrationCanntab therapeuticsFrankfurt stock exchangeTrademark officeClinical research organizationHealth canadaCanadian securities exchangeCanadian intellectual property officeTherapeutics limited